With what we know from CU6 and it’s stage/efficacy does this just not highlight that pharma don’t know know what’s happening in Australia and we fly under the radar unless management go and push awareness for a deal?
Why would astra go and pay $2.4b US for this when CU6 is further along and 1/8 the value.
With what we know from CU6 and it’s stage/efficacy does this...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.005(0.34%) |
Mkt cap ! $250.8M | |||
| Open | High | Low | Value | Volume |
| $1.51 | $1.53 | $1.48 | $125.2K | 83.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 448 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 1300 | 1 |
View Market Depth
| Last trade - 14.26pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.51 |
Change
0.005 ( 0.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.52 | $1.53 | $1.48 | 13157 | ||
| Last updated 15.00pm 21/05/2024 ? | |||||
| RAC (ASX) Chart |